Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.

Extracellular vesicle PD‐L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies

Open access

Abstract

Abstract Programmed cell death 1 ligand 1 (PD-L1) is the ligand for programmed death protein-1 (PD-1), is associated with immunosuppression. Signaling via PD-1/PD-L1 will transmits negative regulatory signals to T cells, inducing T-cell inhibition, reducing CD8 + T-cell proliferation, or promoting T-cell apoptosis, which effectively reduces the immune response and leads to large-scale tumor growth. Accordingly, many antibody preparations targeting PD-1 or PD-L1 have been designed to block the binding of these two proteins and restore T-cell proliferation and cytotoxicity of T cells. However, these drugs are ineffective in clinical practice. Recently, numerous of studies have shown that, in addition to the surface of tumor cells, PD-L1 is also found on the surface of extracellular vesicles secreted by these cells. Extracellular vesicle PD-L1 can also interact with PD-1 on the surface of T cells, leading to immunosuppression, and has been proposed as a potential mechanism underlying PD-1/PD-L1-targeted drug resistance. Therefore, it is important to explore the production, regulation and tumor immunosuppression of PD-L1 on the surface of tumor cells and extracellular vesicles, as well as the potential clinical application of extracellular vesicle PD-L1 as tumor biomarkers and therapeutic targets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12964-021-00816-w

Cites

165 of 165 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Regulation of PD-L1 expression on the surface of tumor cells. Many factors affect the expression of PD-L1 on tumor cell surface, including genomic alterations and epigenetic, transcriptional, post-transcriptional, and post-translational regulatory mechanisms
Fig. 1 Regulation of PD-L1 expression on the surface of tumor cells. Many factors affect the expression of PD-L1 on tumor cell surface, including genomic alterations and epigenetic, transcriptional, post-transcriptional, and post-translational regulatory mechanismsCC BY · PubMed Central
Fig. 2 Abbreviated drawing of the formation process of EV-PD-L1 and its direct and indirect inhibitory effects against T cells. ① The process of Exo-PD-L1 production. ②Microvesicles produced by budding can also carry PD-L1. ③ PD-L1 present on the surface of exosomes secreted by tumor cells directly binds to PD-1 on T cells, inducing an immune checkpoint response that inhibits the activation of T cells and disrupts their function, thus inhibiting antitumor immunity. ④ Exosomes released by tumor cells can mediate the increase of PD-L1 expression on the surface of macrophages, neutrophils or monocytes, and then combine with PD-1 on the surface of T cells to inhibit T cells. ⑤ IFN-γ secreted by T cells can promote the expression of PD-L1 on the surface of tumor cells and exosomes
Fig. 2 Abbreviated drawing of the formation process of EV-PD-L1 and its direct and indirect inhibitory effects against T cells. ① The process of Exo-PD-L1 production. ②Microvesicles produced by budding can also carry PD-L1. ③ PD-L1 present on the surface of exosomes secreted by tumor cells directly binds to PD-1 on T cells, inducing an immune checkpoint response that inhibits the activation of T cells and disrupts their function, thus inhibiting antitumor immunity. ④ Exosomes released by tumor cells can mediate the increase of PD-L1 expression on the surface of macrophages, neutrophils or monocytes, and then combine with PD-1 on the surface of T cells to inhibit T cells. ⑤ IFN-γ secreted by T cells can promote the expression of PD-L1 on the surface of tumor cells and exosomesCC BY · PubMed Central
Fig. 3 The mechanism of action of anti-PD-1/PD-L1 drugs and the potential mechanism underlying the exosomal PD-L1-mediated resistance to anti-PD-L1 drugs. ① Anti-PD-1/PD-L1 drugs can interact with PD-1/PD-L1, free T cells from the checkpoint block, and restore immune responses. ② and ③ Exo-PD-L1 is thought to contribute to resistance during immunotherapy through two mechanisms. In one, exo-PD-L1 binds to anti-PD-L1 monoclonal antibody (mAb), leading to PD-L1 exposure on the tumor surface (②); in the other, Although anti-PD-L1 mAb can interact with PD-L1 on the surface of tumor, exo-PD-L1 can directly interact with PD-1 on the surface of T cells to inhibit immunity (③)
Fig. 3 The mechanism of action of anti-PD-1/PD-L1 drugs and the potential mechanism underlying the exosomal PD-L1-mediated resistance to anti-PD-L1 drugs. ① Anti-PD-1/PD-L1 drugs can interact with PD-1/PD-L1, free T cells from the checkpoint block, and restore immune responses. ② and ③ Exo-PD-L1 is thought to contribute to resistance during immunotherapy through two mechanisms. In one, exo-PD-L1 binds to anti-PD-L1 monoclonal antibody (mAb), leading to PD-L1 exposure on the tumor surface (②); in the other, Although anti-PD-L1 mAb can interact with PD-L1 on the surface of tumor, exo-PD-L1 can directly interact with PD-1 on the surface of T cells to inhibit immunity (③)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 165 references

Research works printed but not linked: 5

  1. Liu C, Gao AC. IFNgamma, a double-edged sword in cancer immunity and metastasis. Cancer Res. 2019;79:1032–3. · DOI
  2. Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I. Dual faces of IFNgamma in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity. Clin Cancer Res. 2016;22:2329–34. · DOI · Paper page
  3. Ju X, Zhang H, Zhou Z, Chen M, Wang Q. Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-a signaling. Exp Cell Res. 2020;396:112315. · DOI
  4. Ni XY, Sui HX, Liu Y, Ke SZ, Wang YN, Gao FG. TGF-beta of lung cancer microenvironment upregulates B7H1 and GITRL expression in dendritic cells and is associated with regulatory T cell generation. Oncol Rep. 2012;28:615–21. · DOI
  5. Guo R, Li Y, Wang Z, Bai H, Duan J, Wang S, Wang L, Wang J. Hypoxia-inducible factor-1alpha and nuclear factor-kappaB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells. Cancer Sci. 2019;110:1665–75. · DOI

Cited by

See all 88

Metadata

Authors
Liu, J., Peng, X., Yang, S., Li, X., Huang, M., Wei, S., Zhang, S., He, G., Zheng, H., Fan, Q., Yang, L., & Li, H.
Affiliations
Fourth Affiliated Hospital of China Medical University (CN)
Corresponding author
  • Yang, Liang
  • Li, Hangyu
Venue
Cell Communication and Signaling
Published
2022-01-28
Volume
20
Issue
1
Pages
14-14
ISSN
1478-811X (ISSN-L)
OpenAlex
W4210407214
Cited by
75
References
165
Citations by year
2026: 23 · 2025: 20 · 2024: 12 · 2023: 7 · 2022: 13
FWCI
1.35
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Communication and Signaling (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81472302)
  • Innovative Research Group Project of the National Natural Science Foundation of China (82003040)
  • Natural Science Foundation of Liaoning Province (2020-BS-103)
  • China Postdoctoral Science Foundation (2020M681016)
  • Xingliaoyingcaijihua Project of Liaoning Province (XLYC1902050)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
Keywords
extracellular vesicles, PD-L1, PD-1/PD-L1 signaling, tumor immune microenvironment, immunosuppression, T cell suppression, tumor markers, therapeutic target, tumor cell secretion
MeSH terms
Extracellular Vesicles, Humans, Neoplasms, Biomarkers, Tumor, CD8-Positive T-Lymphocytes, Tumor Microenvironment, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Extracellular vesicle PD‐L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies. https://app.cochat.ai/papers/10.1186/s12964-021-00816-w
The paper
Liu, J., Peng, X., Yang, S., Li, X., Huang, M., Wei, S., Zhang, S., He, G., Zheng, H., Fan, Q., Yang, L., & Li, H. (2022). Extracellular vesicle PD‐L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies. Cell Communication and Signaling. https://doi.org/10.1186/s12964-021-00816-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.